Our Approved Medicines
October 4, 2022
Meet Our People
Our employees are passionate, innovative, and collaborative. Together, we strive to relieve suffering for people with great needs, but few options.
The Impact of TD
Tardive dyskenisia (TD) is estimated to affect approximately 600,000 people in the U.S. Although it can look or feel different from day to day, TD is a chronic condition and symptoms may be persistent.
Q2 2022 Financial Results
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) financial results for the second quarter ended June 30, 2022 and reiterated financial guidance for 2022.
